<DOC>
	<DOCNO>NCT02968901</DOCNO>
	<brief_summary>The purpose study document effect first line dual oral combination therapy macitentan 10mg tadalafil 40mg pulmonary vascular resistance ( PVR ) treatment-naïve patient newly diagnose pulmonary arterial hypertension ( PAH ) .</brief_summary>
	<brief_title>Clinical Study Evaluating Effects First-line Oral cOmbination theraPy maciTentan tadalafIl Patients With Newly Diagnosed pulMonary Arterial Hypertension ( OPTIMA )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Inclusion Criteria : 1 . Signed informed consent prior studymandated procedure . 2 . Male female ≥ 18 ≤ 75 year age screening . 3 . Initial PAH diagnosis &lt; 6 month prior Day 1 . 4 . Right heart catheterization ( RHC ) perform Day 28 Day 1 ( RHC data obtain study site within time frame , study , i.e. , sign informed consent , acceptable ) , meet follow criterion : Resting mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg . Pulmonary capillary wedge pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) ≤ 15 mmHg . PVR ≥ 400 dyn·sec/cm5 ( ≥ 5 Wood unit ) PCWP &lt; 12 mmHg OR PVR ≥ 500 dyn·sec/cm5 ( ≥ 6.25 Wood unit ) PCWP [ 1215 ] mmHg . Negative vasoreactivity test mandatory idiopathic PAH ( previous RHC ) . 5 . World Health Organization ( WHO ) Functional Class ( FC ) II III . 6 . PAH etiology belong one follow group : Idiopathic . Heritable . Anorexigens induce . Associated one following : Connective tissue disease Congenital heart disease simple systemictopulmonary shunt ( atrial septal defect , ventricular septal defect , patent ductus arteriosus ) ≥1 year surgical repair HIV infection 7 . 6MWD ≥ 50 screening . 8 . Woman childbearing potential [ see definition Section 4.5.1 ] must : Have negative serum pregnancy test screen visit negative urine pregnancy test D1 visit , Agree perform monthly pregnancy test 30 day EOT2 , Agree use reliable contraception [ define Section 4.5.2 ] screen 30 day EOT2 . Reliable contraception must start least 11 day prior Day 1 . 1 . Any PAHspecific drug therapy [ e.g . endothelin receptor antagonist , phosphodiesterase5 inhibitor ( PDE5i ) , soluble guanylate cyclase stimulator , prostacyclin , prostacyclin analog , prostacyclin receptor agonist ] time prior Day 1 ( singledose administration vasoreactivity test permit ; previous iloprost use intermittently treatment digital ulcer Raynaud 's phenomenon permit stop &gt; 6 month prior Day 1 ) . 2 . Subjects change dose discontinued calcium channel blocker within 1 week prior Day 1 . 3 . Initiation diuretic within 1 week prior RCH . 4 . Subjects oral diuretic dose stable least 1 week prior RHC . 5 . Treatment PDE5i erectile dysfunction . 6 . Treatment strong inducer CYP3A4 ( e.g. , carbamazepine , rifampin , rifampicin , rifabutin , rifapentin , phenobarbital , phenytoin , St. John 's wort ) ≤ 28 day prior Day 1 . 7 . Treatment strong inhibitor CYP3A4 ( e.g. , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , nefazodone , ritonavir , boceprevir , telaprevir , saquinavir , lopinavir , fosamprenavir , darunavir , tipranavir , atazanavir , nelfinavir , amprenavir , indinavir ) ≤ 28 day prior Day 1 . 8 . History priapism . 9 . Significant aortic mitral valve disease require specific treatment . 10 . Pericardial constriction . 11 . Lifethreatening arrhythmia . 12 . Uncontrolled hypertension . 13 . Symptomatic coronary artery disease . 14 . Cardiopulmonary rehabilitation program base exercise ( plan , start ≤ 12 week prior Day 1 ) . 15 . Body mass index ( BMI ) &gt; 40 kg/m2 screening . 16 . Acute myocardial infarction ≤ 12 week prior Day 1 . 17 . Known permanent atrial fibrillation . 18 . Low blood pressure &lt; 90/50 mmHg screen Day 1 . 19 . Ongoing plan treatment nitrate and/or doxazosin . 20 . DLCO &lt; 40 % predict value ( eligible sign venoocclusive disease accord adjudication committee ) ; 21 . Presence ≥ 1 follow sign relevant lung disease time prior Day 1 : FEV1/FVC &lt; 70 % FEV1 &lt; 65 % predict bronchodilator administration ; Total Lung Capacity ( TLC ) &lt; 60 % predict . 22 . Known suspicion pulmonary venoocclusive disease ( PVOD ) . 23 . Severe renal insufficiency ( estimate creatinine clearance ≤ 30 mL/min/1.73m² ) assess central laboratory screening . 24 . Ongoing planned dialysis . 25 . Documented severe hepatic impairment ( without cirrhosis ) accord National Cancer Institute organ dysfunction work group criterion , define total bilirubin &gt; 3 x ULN accompany AST &gt; ULN ( assessed central laboratory screen ) and/or ChildPugh Class C. 26 . Serum AST and/or ALT &gt; 3 x ULN ( assessed central laboratory screening ) . 27 . Portopulmonary hypertension . 28 . Hemoglobin &lt; 100 g/L assessed central laboratory screening . 29 . Hypersensitivity active substance excipient macitentan tadalafil formulation . 30 . Loss vision one eye nonarteritic anterior ischemic optic neuropathy ( NAION ) , regardless whether episode connection previous PDE5i exposure . 31 . Hereditary degenerative retinal disorder , include retinitis pigmentosa . 32 . Pregnancy , breastfeeding , intention become pregnant study woman childbearing potential agree use reliable method contraception screen 30 day EOT2 . 33 . Hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 34 . Any factor condition likely affect protocol compliance patient judge investigator . 35 . Treatment another investigational drug ( plan , take ≤ 12 week prior Day 1 ) . 36 . Concomitant lifethreatening disease life expectancy &lt; 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>